BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.

CONTEXT It is uncertain whether intensified heart failure therapy guided by N-terminal brain natriuretic peptide (BNP) is superior to symptom-guided therapy. OBJECTIVE To compare 18-month outcomes of N-terminal BNP-guided vs symptom-guided heart failure therapy. DESIGN, SETTING, AND PATIENTS Randomized controlled multicenter Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) of 499 patients aged 60 years or older with systolic heart failure (ejection fraction < or = 45%), New York Heart Association (NYHA) class of II or greater, prior hospitalization for heart failure within 1 year, and N-terminal BNP level of 2 or more times the upper limit of normal. The study had an 18-month follow-up and it was conducted at 15 outpatient centers in Switzerland and Germany between January 2003 and June 2008. INTERVENTION Uptitration of guideline-based treatments to reduce symptoms to NYHA class of II or less (symptom-guided therapy) and BNP level of 2 times or less the upper limit of normal and symptoms to NYHA class of II or less (BNP-guided therapy). MAIN OUTCOME MEASURES Primary outcomes were 18-month survival free of all-cause hospitalizations and quality of life as assessed by structured validated questionnaires. RESULTS Heart failure therapy guided by N-terminal BNP and symptom-guided therapy resulted in similar rates of survival free of all-cause hospitalizations (41% vs 40%, respectively; hazard ratio [HR], 0.91 [95% CI, 0.72-1.14]; P = .39). Patients' quality-of-life metrics improved over 18 months of follow-up but these improvements were similar in both the N-terminal BNP-guided and symptom-guided strategies. Compared with the symptom-guided group, survival free of hospitalization for heart failure, a secondary end point, was higher among those in the N-terminal BNP-guided group (72% vs 62%, respectively; HR, 0.68 [95% CI, 0.50-0.92]; P = .01). Heart failure therapy guided by N-terminal BNP improved outcomes in patients aged 60 to 75 years but not in those aged 75 years or older (P < .02 for interaction) CONCLUSION Heart failure therapy guided by N-terminal BNP did not improve overall clinical outcomes or quality of life compared with symptom-guided treatment. TRIAL REGISTRATION isrctn.org Identifier: ISRCTN43596477.

[1]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, New England Journal of Medicine.

[2]  B. Yawn,et al.  Trends in heart failure incidence and survival in a community-based population. , 2004, Journal of the American Medical Association (JAMA).

[3]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[4]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[5]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[6]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[7]  C. Frampton,et al.  Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) levels improves outcome , 2000 .

[8]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[9]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .

[10]  J. Pell,et al.  Evidence of Improving Prognosis in Heart Failure: Trends in Case Fatality in 66 547 Patients Hospitalized Between 1986 and 1995 , 2000, Circulation.

[11]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[12]  S. Normand,et al.  National trends in outcomes among elderly patients with heart failure. , 2006, The American journal of medicine.

[13]  H. Krum,et al.  Demographics and concomitant disorders in heart failure , 2003, The Lancet.

[14]  R. Baggott.  DISEASE , 1947, Social Policy & Administration.

[15]  Harlan M Krumholz,et al.  Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.

[16]  John G.F. Cleland,et al.  [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. , 2005, Revista espanola de cardiologia.

[17]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[18]  J. Struck,et al.  Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. , 2008, Journal of the American College of Cardiology.

[19]  M. Cheitlin,et al.  Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study , 2008 .

[20]  J. Cohn,et al.  Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. , 1993, The American journal of cardiology.

[21]  Efficacy, safety and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure , 2004 .

[22]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[23]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[24]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[25]  C. Frampton,et al.  B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction , 2003, Circulation.

[26]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[27]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[28]  G. Lamas,et al.  N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.

[29]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[30]  S. Gottlieb,et al.  Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. , 2004, European heart journal.

[31]  S. Willich,et al.  Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease , 2003, Heart.

[32]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[33]  M A Hlatky,et al.  A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). , 1989, The American journal of cardiology.

[34]  M. Pfisterer,et al.  Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.